Medical Management of Inflammatory Bowel Disease in the Elderly
DOI:
https://doi.org/10.58931/cibdt.2024.2231Abstract
The optimal management of inflammatory bowel disease (IBD) can be challenging at the best of times; however, this notion becomes more salient when treating the niche population of elderly IBD. The prevalence of IBD in elderly Canadians has almost doubled in a span of 5 years, increasing from 1/160 in 2018 to 1/88 in 2023. While the majority of IBD patients are diagnosed between 20-40 years of age, 10-15% are diagnosed at >60 years of age. Elderly-onset ulcerative colitis (UC) patients more commonly have left-sided colitis with less disease extension whereas elderly-onset Crohn’s disease (CD) patients typically exhibit an inflammatory colonic phenotype. Although elderly-onset IBD patients typically demonstrate a less aggressive natural history overall, they have a similar risk of surgery compared to their adult-onset IBD counterparts with the majority being treated with non-advanced therapies. A lack of physician knowledge and comfort level in treating elderly IBD likely contribute to patients being maintained inappropriately on long-term steroids and/or 5-aminosalicylates.
The existing literature on elderly IBD often fails to differentiate between aging pediatric or adult-onset IBD patients and elderly-onset IBD patients; therefore, this article will discuss the management of both groups together. Nevertheless, it is important to note that these two groups likely have different underlying pathophysiological mechanisms driving their respective diseases which can have implications for therapeutic decisions. Unfortunately, the majority of evidence to help guide decision-making in elderly IBD is derived from retrospective analyses of real-world data or health administrative datasets, as well as post-hoc analyses of randomized controlled trials (RCTs). Drug efficacy aside, nuanced care of the elderly IBD patient involves an appreciation of frailty and comorbidity to help contextualize the risks of immunosuppressive therapy. Not only is the safety of therapies contingent upon the intrinsic immunosuppressive properties of the drug, but in addition, drug efficacy needs to be considered with respect to the effectiveness in controlling disease activity and achieving corticosteroid-free remission.
References
Shaffer SR, Kuenzig ME, Windsor JW, et al. The 2023 Impact of inflammatory bowel disease in Canada: special populations-IBD in seniors. J Can Assoc Gastroenterol. 2023;6(Suppl 2) DOI: https://doi.org/10.58931/cibdt.2024.2122
Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11(2):88-98. DOI: https://doi.org/10.1038/nrgastro.2013.240
Rozich JJ, Dulai PS, Fumery M, et al. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18(11):2437-47 e6. DOI: https://doi.org/10.1016/j.cgh.2020.02.048
Meng G, Monaghan TM, Duggal NA, et al. Microbial-immune crosstalk in elderly-onset inflammatory bowel disease: unchartered territory. J Crohns Colitis. 2023;17(8):1309-25. DOI: https://doi.org/10.1093/ecco-jcc/jjad025
Bedard KR, Tandon P, Abraldes, JG, et al. Association between frailty or sarcopenia and adverse outcomes in inflammatory bowel disease: a systematic review. Gastro Hep Advances. 2022;1(2):241-50. DOI: https://doi.org/10.1016/j.gastha.2021.11.009
Kochar BD, Cai W, Ananthakrishnan AN. Inflammatory bowel disease patients who respond to treatment with anti-tumor necrosis factor agents demonstrate improvement in pretreatment frailty. Dig Dis Sci. 2022;67(2):622-8. DOI: https://doi.org/10.1007/s10620-021-06990-8
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95. DOI: https://doi.org/10.1503/cmaj.050051
Toruner M, Loftus EV, Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterol. 2008;134(4):929-36. DOI: https://doi.org/10.1053/j.gastro.2008.01.012
Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30-5. DOI: https://doi.org/10.1016/j.cgh.2010.09.026
Cheng D, Cushing KC, Cai T, et al. Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. Clin Gastroenterol Hepatol. 2021;19(5):939-46 e4. DOI: https://doi.org/10.1016/j.cgh.2020.04.070
Clement B, De Felice K, Afzali A. Indications and safety of newer IBD treatments in the older patient. Curr Gastroenterol Rep. 2023;25(7):160-8. DOI: https://doi.org/10.1007/s11894-023-00874-9
Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019;49(9):1188-94. DOI: https://doi.org/10.1111/apt.15214
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New Engl J Med. 2022;386(4):316-26. DOI: https://doi.org/10.1056/NEJMoa2109927
Sandborn WJ, D'Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the Global Clinical Programme. J Crohns Colitis. 2023;17(3):338-51. DOI: https://doi.org/10.1093/ecco-jcc/jjac141
Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857-73. DOI: https://doi.org/10.1038/s41575-021-00492-8
Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847-58 e4; quiz e48-50. DOI: https://doi.org/10.1016/j.cgh.2015.03.008
Iborra M, Herreras J, Bosca-Watts MM, et al. Withdrawal of azathioprine in inflammatory bowel disease patients who sustain remission: new risk factors for relapse. Dig Dis Sci. 2019;64(6):1612-21. DOI: https://doi.org/10.1007/s10620-018-5429-1
Kochar B, Rusher A, Araka E, et al. Prevalence and appropriateness of polypharmacy in older adults with inflammatory bowel diseases. Dig Dis Sci. 2024.69(3):766-74. DOI: https://doi.org/10.1007/s10620-023-08250-3
Turbayne AK, Sparrow MP. Low-dose azathioprine in combination with allopurinol: the past, present and future of this useful duo. Dig Dis Sci. 2022; 67(12):5382-91. DOI: https://doi.org/10.1007/s10620-022-07719-x
Ng HJ, Crowther MA. Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review. Am J Geriatr Pharmacother. 2006;4(1):75-7. DOI: https://doi.org/10.1016/j.amjopharm.2006.03.001
Tran JQ, Zhang P, Ghosh A, et al. Single-dose pharmacokinetics of ozanimod and its major active metabolites alone and in combination with gemfibrozil, itraconazole, or rifampin in healthy subjects: a randomized, parallel-group, open-label study. Adv Ther. 2020;37(10):4381-95. DOI: https://doi.org/10.1007/s12325-020-01473-0
Menon S, Riese R, Wang R, et al. Evaluation of the effect of tofacitinib on the pharmacokinetics of oral contraceptive steroids in healthy female volunteers. Clin Pharmacol Drug Dev. 2016;5(5):336-42. DOI: https://doi.org/10.1002/cpdd.270
Porcari S, Viola A, Orlando A, et al. Persistence on antitumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging. 2020;37(5):383-92. DOI: https://doi.org/10.1007/s40266-020-00744-3
Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441-51. DOI: https://doi.org/10.1111/apt.13294
Amano T, Shinzaki S, Asakura A, et al. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory boweldisease. Sci Rep. 2022;12(1):5324. DOI: https://doi.org/10.1038/s41598-022-09455-8
Paul S, Roblin X. Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther. 2019;50(3):336. DOI: https://doi.org/10.1111/apt.15312
Singh S, Iversen AT, Allin KH, et al. Comparative outcomes and safety of vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases. JAMA Netw Open. 2022;5(9) DOI: https://doi.org/10.1001/jamanetworkopen.2022.34200
Kochar B, Pate V, Kappelman MD, et al. Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults. Clin Gastroenterol Hepatol. 2022;20(6):1299-305 e5. DOI: https://doi.org/10.1016/j.cgh.2021.08.047
Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality and complications among elderly patients with inflammatory bowel diseases: an analysis of the National Surgical Quality Improvement Program Cohort. Clin Gastroenterol Hepatol. 2016;14(9):1274-81. DOI: https://doi.org/10.1016/j.cgh.2015.11.012
Boyd T, Araka EB, Kochar B, et al. Differences in management and outcomes of older and younger adults with severe ulcerative colitis. J Crohns Colitis. 2024;18(4):570-7. DOI: https://doi.org/10.1093/ecco-jcc/jjad183
Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: Expert Review. Gastroenterol. 2021;160(1):445-51. DOI: https://doi.org/10.1053/j.gastro.2020.08.060
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
